We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Image of Holly Large

Holly Large

Contact Us

Holly Large is a PhD student at the University of Leicester, with interests in public health genomics and science communication. Before joining the University of Leicester she worked as Technology Networks' editorial assistant. In her role as editorial assistant Holly supported the publication’s in-house writers.

Latest Content

Rapid COVID-19 Vaccine Development Enabled by Previous Research Investments, Study Suggests

According to a new study published in Vaccine, the rapid pace of COVID-19 vaccine development was enabled by pre-pandemic research on vaccine technologies funded by over $17 billion from the National Institutes of Health.

Rare Blood Clotting Disorder Risk Higher Following COVID-19 Than Post-Vaccination

The risk of rare blood clotting in the brain post-COVID-19 infection is several times higher than it is following COVID-19 vaccination, according to a preprint from researchers at the University of Oxford.

UK Government-Funded COVID-19 Vaccine Phase I/II Trials Report Positive Data

A new COVID-19 vaccine candidate – VLA2001 – developed by Valneva has shown positive results in a UK Government-funded Phase I/II clinical trial, according to a press release.

New Survey Highlights Public Support for Donation of COVID-19 Vaccines to Low-Income Countries

A new study suggests that most people in high-income countries generally support the donation of some of their nation’s COVID-19 vaccine supplies to low-income countries.

New Data Suggests UK’s COVID-19 Vaccination Program Has Prevented Thousands of Elderly Deaths

An analysis by Public Health England (PHE) exploring the impact of COVID-19 vaccines on mortality has found that, from December 2020 to the end of February 2021, England’s COVID-19 vaccination program prevented 6100 deaths in individuals aged 70 and older.

Existing Vaccines May Protect Against New SARS-CoV-2 Variants

A new preprint study posted to bioRxiv suggests that the existing Oxford–AstraZeneca and Pfizer–BioNTech vaccines may still provide protection, albeit at a lower level, against emerging variants of SARS-CoV-2.

New Vaccine Development Partnerships Established To Tackle SARS-CoV-2 Variants

The Coalition for Epidemic Preparedness (CEPI) has announced collaborations with VBI Vaccines (VBI) and SK bioscience to develop vaccine candidates against variants of SARS-CoV-2, including the South African variant.

Single Dose of Pfizer or Oxford Vaccine May Significantly Reduce Risk of Elderly COVID-19 Hospitalizations

A new preprint study suggests that a single dose of either the Pfizer–BioNTech or Oxford University–AstraZeneca vaccine can substantially reduce the risk of COVID-19-related hospitalizations in the elderly.

Supporting the Next Generation of Scientists

We’ve compiled a list of guides and articles to help those at the beginning of their career, spanning a whole range of topics, from grad school and the publication process to mental health and gender inequality.

Opinionated Science Episode 9: The Ethics of Genetics Testing: “Duty of Care”, Consent and Data Security

Advances in genetic testing have come with a lot of ethical baggage. In this podcast we discuss how clinical testing can throw up surprise results for doctor and patient, the test data that is helping fight COVID-19 and how one of our own editors responded to receiving her genetic risk scores.